As we await the results of the ongoing phase III randomized trial (NCT02013648), it is imperative to consider dasatinib as a viable option in the treatment protocol for CBF‐AML patients, potentially setting a new standard of care and improving patient outcomes in this challenging subset of AML. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.